October 2025 in “Dermatology and Therapy” Ritlecitinib is being tested for effectiveness and safety in treating severe alopecia areata.
September 2025 in “Dermatology and Therapy” Baricitinib is a promising treatment for alopecia areata in the UAE, but there are challenges with data and access.
August 2025 in “American Journal of Clinical Dermatology” Clinicians should use evidence-based tools and consider mental health when assessing alopecia areata to guide treatment.
January 2025 in “Universidad de Córdoba Insitutional Repository (Universidad de Córdoba)” An imbalanced scalp microbiome may worsen alopecia areata severity and inflammation, but treatment can partially restore balance.
September 2024 in “Drugs & Therapy Perspectives” Ritlecitinib effectively regrows hair in severe alopecia areata and is well tolerated.
April 2024 in “Frontiers in pharmacology” Brepocitinib 30mg is most effective for moderate-to-severe alopecia areata, but ritlecitinib 50mg may offer a better balance of safety and effectiveness.
September 2023 in “Dermatology and therapy” Ritlecitinib effectively improves hair growth in alopecia areata patients, regardless of hair loss pattern.
Various treatments exist for hair loss, but no definitive solution.
June 2023 in “Dermatology and therapy” Doctors in the Middle East need better treatments and more knowledge about new therapies for hair loss condition Alopecia Areata.
January 2023 in “International Journal of Pharmaceutical Research and Development” Nanotechnology therapies can help improve quality of life for those with hair loss.
December 2022 in “Revista Medicina Cutánea Ibero-Latino-Americana” JAK inhibitors help treat alopecia areata but have high recurrence after stopping.
March 2018 in “Suez Canal University Medical Journal” New drugs targeting the JAK-STAT pathway show promise for treating inflammatory skin diseases.
October 2012 in “Sax's Dangerous Properties of Industrial Materials” 
June 2023 in “British Journal of Dermatology” The prototype for analyzing skin aging works technically and clinically.
February 2023 in “Default Digital Object Group” April 2011 in “Reactions Weekly” 
January 2007 in “대한피부과학회지” The document's conclusion can't be summarized because the text is not in English and the document content is not provided.
March 2005 in “European Urology Supplements” 
July 2004 in “Hair transplant forum international” The document's conclusion cannot be provided because the document is not available for parsing.
January 2009 in “Yaowu fenxi zazhi” The method accurately and reliably detects residual solvents in Finasteride.
February 2026 in “European Urology” May 2026 in “Inflammopharmacology” 1 citations
,
July 2025 in “Journal of Investigative Dermatology” September 2023 in “Zenodo (CERN European Organization for Nuclear Research)” The document's conclusion cannot be determined because the content is not available.
January 2026 in “Animal Genetics” A genetic variant in the GJB6 gene likely caused the Labrador's paw pad condition.
Compound 6 is a promising candidate for better wound healing.
January 2013 in “CINECA IRIS Institutial research information system (University of Pisa)” July 2025 in “Journal of Investigative Dermatology” 23 citations
,
October 2008 in “Journal of medicinal chemistry” PF-998425 is a new, effective, and non-phototoxic treatment for skin conditions related to androgens.
January 2018 in “Journal of analytical, bioanalytical and separation techniques”